Astrocytoma Brain Tumor: Treatment Offers Hope with DCA

by Glioblastoma Prognosis on September 16, 2010

New Press Conference From University of Alberta

Astrocytoma brain tumor begins in star-shaped brain cells called astrocytes.  It does not usually spread outside the brain and spinal cord or affect other organs.  Astrocytoma brain tumors are also known as glioblastomas.  People can develop an astrocytoma brain tumor at any age.  There is a 4 tiered grading system with 1 being the least aggressive and, therefore, having the best survival rates.  As the grade of the astrocytoma brain tumor increases, the treatment options and prognosis worsen. 

Unfortunately, there is no known cause of  an astrocytoma brain tumor, so prevention is not an option. 

Astrocytoma brain tumor treatment includes surgery, chemotherapy, radiation, radiosurgery and/or an intense drug  regiment depending on the age of the patient, the patient’s overall health, the patient’s functional abilities, and the location, seriousness, and type of the specific astrocytoma brain tumor.   

A new compound, DCA (sodium dichloroacetate),  offers hope to those suffering from an astrocytoma brain tumor or other cancers.

DCA is also known as NaDCA, Sodium Dichloroacetate, and Dichloroacetate.  It is a small, simple molecule that the body can easily absorb and its small size enables it to cross the blood-brain barrier and reach the astrocytoma brain tumor when other conventional drugs have not been able to.  

DCA has been used for more than 20 years in the treatment of lactic acidosis.   DCA is odorless, non-toxic, and has been proven to be safe in both healthy and sick people.   As in cases of  lactic acidosis, the cells of an astrocytoma brain tumor have an impaired mitochondria.  When the mitochondria is reactivated using a DCA solution  (pure DCA powder in water), the tumor mass shrunk up to 70% in just 3 weeks.  This was proven at the University of Alberta (UA) in Canada in 2007 by a research team led by Dr. Evangelos Michelakis.    

Dichloroacetate (DCA) cannot be patented  because it is a small and simple compound.    Because DCA cannot be patented, drug companies are not interested in doing clinical trials – Simply put, there is no money in it for them!  DCA is readily available and inexpensive.   However, due to the protectionist design of  governing bodies, without extensive clinical trials, the government cannot sanction the use of DCA.  So, a potential life-saving compound exists but patients and the populace at large are not  educated on this compound.  

Dr. Michelakis has been supported by the Canadian Institutes for Health Research, the Canada Foundation of Innovation, the Canada Research Chairs program, the Alberta Heritage Foundation for Medical Research and other private sources.  

DCA (dichloroacetate) has been used over a period of 1 year to treat 180 patients with cancer, who mostly exhausted all other methods of treatment. 52% of the patients were male and 48% were female. The patients were from 2 years to 90 years old, with the largest group of 56% ranging from 50 to 69 years of age. The forms of cancer ranging from lung (40 patients), astrocytoma brain tumor (26), colon (25), breast (15) to pelvis (1), spine (1) and thyroid (1) cancers, to name just a few.

To view details of the study, the news releases at the time, or learn more about this revolutionary brain tumor treatment use for DCA go to   There are 3 news report from Global News, CTV News, and the Real Story.   These reports explain the medical findings as well as explain why it has not yet, at the time of this writing, become a regular treatment for astrocytoma brain tumor sufferers.

Previous post:

Next post: